For more information, visit www.survivegbm.org
SurviveGBM is a multi-center initiative that we have undertaken to critically examine the molecular profiles of long-term glioblastoma survivors. This is a multinational, multi-center collaborative effort bringing together cross-functional teams with the common goal of identifying key factors that confer survival advantage for certain patients with glioblastoma.
As part of this study, we are evaluating genomic, molecular and physiologic profiles of tumors from long-term survivors of glioblastoma (survival of more than 5 years). We collect samples from patients and examine factors that may provide survival advantage to these glioblastoma patients. We are also collecting the clinical/treatment histories, imaging, pathology specimens, and molecular information. Our team then reviews these data centrally to identify factors that predict improved survival. In patients that are alive, we perform additional studies including advanced imaging, immunological profiling, exosome profiles and others as feasible.
SANTOSH KESARI, MD, PhD
TRANSLATIONAL NEURO-ONCOLOGY LABORATORIES (TNOL)